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Mycoplasma and Ureaplasma species are well-known
human pathogens responsible for a broad array of
inflammatory conditions involving the respiratory
and urogenital tracts of neonates, children, and
adults. Greater attention is being given to these organ-
isms in diagnostic microbiology, largely as a result of
improved methods for their laboratory detection,
made possible by powerful molecular-based tech-
niques that can be used for primary detection in clin-
ical specimens. For slow-growing species, such asMy-
coplasma pneumoniae and Mycoplasma genitalium,
molecular-based detection is the only practical means
for rapid microbiological diagnosis. Most molecular-
based methods used for detection and characteriza-
tion of conventional bacteria have been applied to
these organisms. A complete genome sequence is
available for one or more strains of all of the impor-
tant human pathogens in the Mycoplasma and Urea-
plasma genera. Information gained from genome
analyses and improvements in efficiency of DNA se-
quencing are expected to significantly advance the
field of molecular detection and genotyping during
the next few years. This review provides a summary
and critical review of methods suitable for detec-
tion and characterization of mycoplasmas and ure-
aplasmas of humans, with emphasis on molecular
genotypic techniques. (J Mol Diagn 2012, 14:437–450;
http://dx.doi.org/10.1016/j.jmoldx.2012.06.001)The bacteria commonly referred to as mycoplasmas are
included within the phylum Tenericutes, class Mollicutes,
which is composed of four orders, five families, eight
genera, and approximately 200 known species distrib-
uted among humans, animals, insects, and plants.1 Mol-
licutes are smaller than conventional bacteria, in cellular
dimensions and genome size, making them the smallest
free-living organisms known. Lack of a cell wall, coupled
with their extremely small genome and limited biosyn-
thetic capabilities, explains the parasitic or saprophytic
existence of these organisms, their sensitivity to environ-
mental conditions, resistance to -lactam antibiotics, and
fastidious growth requirements. Among the mollicutes
that are themost important human pathogens, there are one
or more type strains for which the genome has been com-
pletely sequenced and annotated. Genome sizes range
from 580 to 2200 kbp, withMycoplasma genitalium being the
smallest.2 Mollicutes require enriched growth medium sup-
plemented with nucleic acid precursors, fatty acids, and
amino acids. Most mollicutes require sterols in growth me-
dia, supplied by the addition of horse or bovine serum.
There are 16 mollicute species that have been isolated
from humans, excluding those of animal origin that have
been detected occasionally in humans, usually in immuno-
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sient colonizers. There are at least six species considered
to be of pathological significance, either as primary patho-
gens or opportunists: Mycoplasma pneumoniae, Myco-
plasma hominis, M. genitalium, Mycoplasma fermentans,
Ureaplasma urealyticum, and Ureaplasma parvum. A newly
described species, Mycoplasma amphoriforme, has been
detected in the lower respiratory tracts of several immuno-
deficient people with respiratory disease, but there is no
conclusive evidence that this mycoplasma is a significant
pathogen of humans.1 Other species, such asMycoplasma
penetrans and Mycoplasma pirum, have been studied be-
cause of a possible association with HIV and AIDS, but
there is no evidence that either species is independently
pathogenic in humans.3 Although M. fermentans can be
considered an uncommon opportunistic pathogen of hu-
mans,3 it is rarely sought; methods for detection by culture
are not well described, and few laboratories offer molecular-
based tests for its detection. This article focuses on molec-
ular methods for detection and identification of M. pneu-
moniae, M. genitalium, M. hominis, U. parvum, and U.
urealyticum, because these are the mollicute species that
are most important clinically and for which diagnostic test-
ing is most commonly performed.
Major Pathogenic Mollicutes of Humans
A brief summary describing important biological charac-
teristics of each species and salient clinical features of
the infections they cause is provided. Readers are re-
ferred to other reference texts and reviews for more de-
tailed descriptions.3–9
M. pneumoniae
This mycoplasma is a common cause of upper and lower
respiratory tract infections in children and adults. The
organism is easily spread through respiratory droplets
and can cause a variety of clinical manifestations, includ-
ing pharyngitis, tracheobronchitis, and pneumonia. Ex-
trapulmonary manifestations sometimes occur after pri-
mary respiratory tract infection, either by direct spread or
autoimmune effects.4,8 Attachment of M. pneumoniae to
host cells in the respiratory tract is required for coloniza-
tion and infection. Cytadherence is mediated by the P1
adhesin and other accessory proteins, followed by induc-
tion of chronic inflammation, and cytotoxicity is mediated
by hydrogen peroxide, which also acts as a hemolysin.
M. pneumoniae stimulates B and T lymphocytes and in-
duces formation of autoantibodies that react with a vari-
ety of host tissues and the I antigen on erythrocytes,
which is responsible for production of cold agglutinins.4
An ADP-ribosylating toxin, known as the community-ac-
quired respiratory distress syndrome (CARDS) toxin,
causes vacuolation and ciliostasis in cultured host cells
and is becoming appreciated as a significant virulence
factor.10 Although mycoplasmas are generally consid-
ered to be extracellular organisms, intracellular localiza-
tion is appreciated for M. pneumoniae and other species,
including M. genitalium.11,12 Intracellular localization maybe responsible for protecting the organisms from anti-
bodies and antibiotics, as well as contributing to disease
chronicity and difficulty in cultivation. The genome of M.
pneumoniae M129 (type strain for subtype 1) consists of
816 kbp with 687 protein-coding genes.13 The 811-kbp
genome sequence of the FH strain (type strain for sub-
type 2) was published in 2010,14 and the third complete
genome of M. pneumoniae strain 309 from Japan, classi-
fied as subtype 2a variant, consists of 817 kbp.15 A brief
comparison of the three genomes indicated that they are
similar, with variations in a region involving insertion
changes in the putative lipoprotein genes.15 Comparative
analysis of genomic differences among the type strains
and the inclusion of clinical strains representing all of the
major P1 subtypes could provide useful information in
developing diagnostic tests and treatment strategies.
M. genitalium
This mycoplasma was initially isolated from men with ure-
thritis and is a significant cause of this condition and female
cervicitis and pelvic inflammatory disease.9 Unlike other
genital mycoplasmas that are rather common as commen-
sals in the lower urogenital tract of many healthy adults, M.
genitalium is less commonly detected in the absence of
clinical infection. M. genitalium possesses a terminal struc-
ture, the MgPa adhesin, that facilitates its attachment to
epithelial cells,16 attaches to spermatozoa and erythro-
cytes, and invades epithelial cells with evidence of nuclear
localization.9 A family of repetitive DNA elements homolo-
gous to the MgPa adhesin gene is believed to contribute to
variation in the protein of the MgPa adhesin gene. Se-
quence divergence among strains of M. genitalium and an-
tigenic variation may help avoid the host immune response
and optimize adhesion.17 The 580-kbp genome of M. geni-
talium contains only 485 protein-coding genes, making it the
smallest known free-living microorganism.
M. hominis
Approximately 21% to 53% of asymptomatic sexually ac-
tive women are colonized with this mycoplasma in the
cervix or vagina, but the occurrence is somewhat lower in
the male urethra.3 M. hominis is often present concur-
rently with Ureaplasma species and is transmissible ve-
nereally and vertically. M. hominis is associated with a
variety of conditions, including pyelonephritis, pelvic in-
flammatory diseases, chorioamnionitis, postpartum en-
dometritis bacterial vaginosis, arthritis, osteoarthritis,
wound infections, and several conditions in neonates (eg,
congenital pneumonia, meningitis, bacteremia, and ab-
scesses). Systemic infections sometimes occur in neo-
nates, older children, and adults. Such extragenital infec-
tions outside of the neonatal period are usually, but not
always, associated with an immunocompromised host
status.3 Henrich et al18 demonstrated the presence of the
variable adherence-associated antigen, which displays
high-frequency phase and size variation that is believed
to be a major adhesin of M. hominis and may also assist
in evasion of host immune responses. Additional surface
proteins, such as OppA, which is an oligopeptide per-
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involved in cytadherence and may also induce ATP re-
lease from cells, resulting in apoptosis.19 The M. hominis
genome contains 665 kbp and 527 protein-coding
genes, placing it second, behind M. genitalium, as the
smallest known self-replicating free-living organism.19
Genome analysis indicates that M. hominis has under-
gone horizontal gene transfer with Ureaplasma species.19
U. parvum and U. urealyticum
Members of the genus Ureaplasma hydrolyze urea and use
it as ametabolic substrate for generation of ATP. This genus
has seven recognized species, with U. parvum and U. urea-
lyticum being the two species found in humans. As many as
40% to 80% of healthy adult women may harbor ureaplas-
mas in their cervix or vagina. Their occurrence is somewhat
less in the lower urogenital tract of healthy men.3 The or-
ganisms are readily transmitted venereally and vertically,
either in utero or at delivery of the neonate.3 U. parvum is
more common thanU. urealyticum as a colonizer of themale
and female urogenital tracts and in the neonatal respiratory
tract.3 Although detected less frequently than U. parvum in
most patient populations, U. urealyticum may be more
pathogenic in male urethritis.3,20 Ureaplasmas reside pri-
marily on the mucosal surfaces of the urogenital tracts of
adults or the respiratory tracts in infants. Despite their fre-
quent occurrence in healthy people, Ureaplasma species
may cause or be associated with a variety of clinical con-
ditions in adults, including urethritis, arthritis, chorioamnio-
nitis, postpartum endometritis as well as preterm birth,
pneumonia, bacteremia, abscesses, meningitis, and
chronic lung disease in neonates.3 Systemic spread is un-
common beyond the neonatal period unless there is an
immunosuppressed condition, such as hypogammaglobu-
linemia.3,21 Ureaplasmas are capable of attaching to a va-
riety of cell types, such as urethral epithelial cells, sperma-
tozoa, and erythrocytes.3 The adhesins of ureaplasmas
have not been characterized completely, but evidence sug-
gests that the receptors are sialyl residues and/or sulfated
compounds.3 A major family of surface proteins, the multi-
ple-banded antigens, is immunogenic during ureaplasmal
infections. Ureaplasmas produce an IgA protease and re-
lease ammonia through urea hydrolysis, both of which are
considered possible virulence factors.3 Variation in surface
antigens may be related to persistence of these organisms
at invasive sites. Details of the pathogenic mechanisms
through which ureaplasmas mediate human disease have
been described elsewhere.3 Ureaplasma genomes range
from 750 kbp (594 genes) for U. parvum to 947 kbp (711
genes) for U. urealyticum.
Limitations of Culture and Serological
Analysis as Diagnostic Tests for
Mycoplasmas and Ureaplasmas
Culture
Ureaplasma species grow rapidly in media containing
urea, such as 10 B broth and A 8 agar, producing colo-nies visible with a stereomicroscope within 1 to 3 days.1
The appearance of brown granular colonies on A 8 agar
is sufficient for the diagnosis of Ureaplasma species, but
culture alone cannot distinguish between the two spe-
cies. M. hominis grows well in SP 4 broth or SP 4 agar
supplemented with arginine, but it will also grow on A 8
agar and in 10 B broth.1 Colonies appear on agar within
2 to 3 days, visible with a stereomicroscope. To confirm
species identity for mycoplasmas growing on agar, ad-
ditional procedures (eg, a PCR assay) must be per-
formed because there are no phenotypic tests that can
distinguish them.
PCR is more sensitive than culture for diagnostic pur-
poses, even for organisms such as M. hominis and Urea-
plasma species, which are relatively easily and quickly
cultivated. Data from the University of Alabama at Birming-
ham Diagnostic Mycoplasma Laboratory showed that real-
time PCR detected ureaplasmal DNA in 52 (39.4%) of 132
specimens versus 32 (24.2%) detected by culture.22 Even
though culture was considered the reference method, PCR
is theoretically able to detect fewer organisms; therefore,
PCR-positive, culture-negative specimens likely represent
true positives.
Despite PCR being more sensitive for detection of M.
hominis and Ureaplasma species, culture remains the
most economical and practical means for detection of
these organisms for most laboratories with a low to mod-
erate test volume. Cultures can be set up one at a time,
whereas the most efficient and cost-effective use of PCR
is to run the assays in batches of several specimens.
However, batching lengthens the turnaround time for re-
porting results. Culture also has additional advantages in
that it provides an isolate on which antimicrobial suscep-
tibility testing can be performed. Highly sensitive PCR as-
says are useful for research studies when turnaround time is
not so critical and when samples can be batch tested for
cost-effectiveness. Although various modalities have been
developed to enhance the ability to detect M. genitalium in
culture, the high failure rate and extremely slow growth
make culture impractical and rarely attempted now that
molecular-based assays have been developed.
M. pneumoniae can be cultivated in SP 4 glucose
broth, although its slow growth, requiring several days to
weeks, and low sensitivity make culture unattractive for
diagnostic purposes.1 Colonies growing on agar must
undergo additional testing, typically by PCR, to confirm
their identity because several commensal mycoplasmal
species often inhabit the human oropharynx. Isolation of
the organism from the respiratory tract or detection of its
DNA is clinically significant in most instances. This should
be correlated with the presence of clinical respiratory
tract disease, because occasional asymptomatic carriers
may exist.
Detailed methods for obtaining specimens, culturing,
and identifying mycoplasmas and ureaplasmas of hu-
mans in vitro using culture-based methods have been
described in other reference texts.1,23 Whether culture- or
non–culture-based detection methods should be used
for diagnostic purposes depends on the resources and
facilities available in individual laboratories and the spe-
cies being sought.
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Serological testing was the first method developed for de-
tection of M. pneumoniae infections. Complement fixation
assays were used for many years until the development of
alternative serological methods sold commercially, such as
enzyme immunoassays, immunofluorescence, and particle
agglutination assays. More recently, molecular-based nu-
cleic acid amplification tests (NAATs) have further reduced
the need for serological diagnosis. Despite its widespread
use, at least partly because of the expense and limited
availability of NAATs, serological analysis has far more
limitations than advantages for detection of acute M.
pneumoniae infections. The main disadvantages of sero-
logical analysis are the requirement for acute and con-
valescent serum samples that are tested simultaneously
for IgM and IgG to confirm seroconversion, difficulty in
distinguishing current or recent infection from past infec-
tion, and need to wait 1 to 2 weeks from onset of the
infection until detectable antibody develops.24 Adults
may never develop a measurable IgM response, presum-
ably because of reinfections.4 Moreover, IgM antibodies
can persist for weeks to months, making it risky to base
diagnosis of acute infection on a single assay for IgM.4 In
addition, as a result of repeated infections, many healthy
adults can also have a high background seropositivity for
IgG25; thus, there is a need to measure antibody increase
and decrease in acute and convalescent specimens.
Antibody production may also be delayed in some infec-
tions or even absent if the patient is immunosuppressed.
Problems with sensitivity and/or specificity have been
reported for practically all serological assay formats and
commercial products when rigorously compared with
other detection methods, such as PCR.24 However, many
serological tests have never undergone extensive com-
parative evaluations and comparison with other diagnos-
tic methods, so their accuracy is unknown. Serological
testing of M. pneumoniae and the various commercial
methods available for antibody measurement have been
described in other reference texts and reviews.1,4,23,24
Serological test methods for M. hominis, Ureaplasma
species, and M. genitalium include microimmunofluores-
cence, metabolism inhibition, and enzyme immunoas-
say,1 but the ubiquity of ureaplasmas and M. hominis in
healthy people makes interpretation of antibody titers
against these organisms difficult. No serological assays
for the genital mycoplasmas have been standardized,
and they are not available in the United States for diag-
nostic purposes.
Overview of Molecular-Based Tests for
Detection of Mollicutes
Interest in non–culture-based detection of mycoplasmas
dates back to the 1980s when assays for M. pneumoniae
antigen detection and nonamplified DNA probes were
developed, driven by the drawbacks of culture and se-
rological analysis. Once NAATs began to be developed,
interest in nonamplified DNA probes and antigen detec-
tion assays waned, and there are no products of thisnature sold commercially in the United States for detec-
tion of M. pneumoniae.
Since 1989, hundreds of publications have described
various NAATs and their applications to detect mycoplas-
mas and ureaplasmas in clinical specimens. These as-
says enable detection of extremely fastidious species,
such as M. genitalium, that might never be detected oth-
erwise. NAATs are also useful for the identification of
organisms grown in culture to the species level, replacing
older and cumbersome technologies.
PCR is the most widely applied NAAT for detection of
mycoplasmas and ureaplasmas. PCR has also been
adapted to detect antimicrobial resistance determinants
and to analyze genetic relatedness of clinical isolates.
Conventional PCR measures the end-stage PCR prod-
ucts using gels or other methods, whereas real-time PCR
detects and quantifies the products simultaneously with
amplification. Nested PCR can increase sensitivity
through re-amplification of a PCR product with a second
set of primers.26 However, the nested PCR method may
also enhance the risk of contamination.27 Publications
describing real-time PCR for detection and characteriza-
tion of mycoplasmas and ureaplasmas have used the ABI
Prism 7900HT (Applied Biosystems, Carlsbad, CA), the
iCycler iQ (Bio-Rad, Hercules, CA), and the LightCycler
2.0 (Roche Diagnostics, Indianapolis, IN). Detection sys-
tems include agarose gel electrophoresis, SYBR Green,
TaqMan probes, hybridization probes, molecular bea-
cons, and microchip electrophoresis (Foster City, CA).28
The UAB Diagnostic Mycoplasma Laboratory has elimi-
nated conventional PCR in favor of real-time PCR using
the Roche LightCycler for detection and identification of
all of the major mollicute pathogens of humans because
of its advantages in accuracy, quantitation, and turn-
around time. The improved specificity of real-time PCR
compared with conventional PCR is mainly because of
the use of a third oligonucleotide probe that binds to the
target sequence. The use of a labeled probe minimizes
the probability of cross-reaction and detection of unde-
sired amplicons. Another feature of real-time PCR that
contributes to the specificity of the assay is that the am-
plicon melting temperature is determined at the end of
the assay, so it can be used to verify whether the desired
PCR product is being detected.
Because organism viability does not have to be main-
tained for NAAT-based detection, specimen collection,
handling, and transport are somewhat simpler than for
culture, in that a specialized nutritive transport medium is
not required. Although conventional PCR methods can
take 2 to 3 days, real-time PCR can potentially provide
results the same day a specimen is received and provide
quantitative data to determine the bacterial load. This can
be important for interpretation of results for organisms
that are known to colonize asymptomatic people. Two
studies have reported that the bacterial load of M. pneu-
moniae in throat swabs was significantly greater in pa-
tients requiring hospitalization than in those who were not
hospitalized, indicating the potential importance of such
quantitative data.29,30 The pros and cons of NAATs, cul-
ture, and serological analysis, as they apply to detection
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are summarized in Table 1.
Use of Molecular-Based Tests for Mollicute
Detection
M. pneumoniae
Gene targets for PCR assays have included 16S ribo-
somal RNA (rRNA), P1, tuf, parE, dnak, pdhA, ATPase
operon, CARDS toxin gene (mpn372), and the noncoding
repetitive element repMp1.6,26,28,31–33 Analytical sensitiv-
ity is generally high, with some assays being capable of
detecting a single organism when purified DNA is used.
The UAB Diagnostic Mycoplasma Laboratory adapted
the real-time PCR assay published by Dumke et al,32
Table 1. Advantages of Molecular-Based Methods Compared wi
Ureaplasmas in Humans
Criteria Molecular-based assays
Availability Not commercially available in the
United States, a few PCR kits
are available in Europe and
Asia. Nonproprietary PCR
assays are available in a few
US reference laboratories.
Commerc
and A 8
M. hom
species
availab
and ref
Addition
genotyp
confirm
colony
Cost Cost of equipment and reagents
is significant, and personnel
trained in molecular diagnosis
are required. Costs are less if
equipment, facilities, and
personnel can be used for
other molecular diagnostic
testing.
Media are
obtain o
used fo
purpose
Length
be held
mycopl
costs.
Turnaround
time
Real-time PCR can be
completed in a few hours.
Batching specimens and
running the assays once or
twice each week decrease the
costs but delay turnaround
time.
M. homini
can be
1–3 day
pneumo
up to se
genitaliu
grown i
Analytical
sensitivity
High: most assays detect 100
CFU/mL organisms or 100
genome copies.
May dete
organis
Specificity PCR assays that are carefully
validated with targets chosen
for diagnostic accuracy and
lack of cross-reactivity are
specific.
Culture is
positive
Specimen
requirements
Organisms do not have to be
viable. The same specimen
types used for culture can be
submitted for PCR assays.
Specimens require frozen
storage until processing.
Formalin-fixed tissue can also
be processed by PCR.
Properly c
require
media,
shipme
ELISA, enzyme-linked immunosorbent assay.targeting the repMp1 noncoding DNA sequence for rou-tine diagnostic use. Its theoretical advantage is the fact
that sensitivity may be improved by amplification of a
gene present in multiple copies. This assay provided
acceptable sensitivity and specificity when tested
against several M. pneumoniae reference strains, detect-
ing as few as seven DNA molecules per microliter, in-
cluding both major P1 subtypes. The assay also detected
M. pneumoniae DNA in a large group of clinical speci-
mens obtained from patients with radiologically proved
pneumonias who were positive for M. pneumoniae by
serological analysis, culture, and/or conventional PCR.
No other mollicute species or other respiratory pathogens
tested positive by this method.32,34
Use of PCR for detection of M. pneumoniae infection in
extrapulmonary sites can also be helpful because cul-
tures from nonpulmonary sites are rarely positive as a
re and Serological Analysis for Detection of Mycoplasmas and
ulture Serological analysis
epared SP 4, 10 B,
and test kits for
Ureaplasma
ailable. Culture is
any large hospital
laboratories.
unoserological or
s are required to
s identity of large-
lasmas.
Commercial qualitative and quantitative
antibody assays are available for M.
pneumoniae. No such assays are
available for other Mycoplasma or
Ureaplasma species in the United
States.
what expensive to
are. Equipment
ral microbiology
ually sufficient.
cultures have to
w-growing
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Commercial serological kits for M.
pneumoniae vary in cost. Some
assay formats are suitable for testing
single specimens, whereas others
are more practical for batches. Cost
per test depends on the volume of
specimens and equipment
requirements.
reaplasma species
in culture within
reas M.
quires from 5 days
weeks. M.
not be reliably
re.
Hands-on time varies from a few
minutes to a few hours. Acute and
convalescent serum sample
collection time spans 2–3 weeks.
1000 viable
test.
Serological tests do not measure the
presence of the microorganism, but
instead measure the host immune
response. Compared with PCR,
serological analysis may miss many
infected individuals.
specific when Older complement fixation tests had
problems distinguishing M.
pneumoniae from M. genitalium.
Newer commercial ELISAs do not
have this problem.
d specimens
riate transport
storage, and
aintain viability.
Serum is the only required specimen
type. No special handling or storage,
other than refrigeration, is needed.th Cultu
C
ially pr
media
inis and
are av
le in m
erence
al imm
ic test
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mycop
some
r prep
r gene
s is us
of time
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illness for an antibody response to develop and for test-
ing fixed lung tissue obtained at biopsy.6 The advantage
of real-time PCR over conventional PCR in detection of
systemic infection was demonstrated in a study that
found 15 (52%) of 29 patients with serological evidence
of M. pneumoniae infection had a positive assay result
when serum samples were tested by real-time PCR. Con-
ventional PCR assay results for those specimens were
entirely negative.35
Although PCR may theoretically be more sensitive than
culture, some studies have yielded contradictory results.6
For PCR-positive, culture-negative patients, it is important
to ascertain whether clinically significant respiratory dis-
ease is actually present, because the positive PCR assay
result may reflect asymptomatic carriage with a low bac-
terial load, prior antibiotic therapy, persistence of myco-
plasmal DNA after resolution of infection, organisms re-
siding in an intracellular location not amenable to culture,
or the possibility that the PCR target was nonspecific. A
positive PCR assay result in a patient who is serologically
negative may indicate that the specimen was obtained
too early in the infection for measurable antibody to have
developed, antimicrobial therapy that may have blunted
the immune response, or an inadequate immune re-
sponse because of immunosuppression. Negative PCR
results in patients who are culturally and/or serologically
positive could indicate technical problems with the PCR
assay or inhibitors. Using a PCR assay with a different
gene target may resolve the problem. One issue that can
be problematic with PCR assays forM. pneumoniae is that
they may not have been tested adequately for specificity
for this organism by making certain there is no reactivity
with the numerous commensal mycoplasmal species of
the human respiratory tract. The use of a highly specific
PCR forM. pneumoniae has been particularly useful in our
experience when mycoplasma species are detected in
respiratory tract cultures because they frequently turn out
to be one of the common commensal species and not M.
pneumoniae. Performing PCR assays with two different
gene targets is theoretically the best diagnostic ap-
proach for M. pneumoniae infections, but using the sec-
ond target increases costs and takes more time. Com-
bining PCR with serological analysis has also been
advocated as a possible means to distinguish colonization
from active disease, but this also adds to the cost of testing
and will not overcome the problem common in older people
who often fail to mount an acute-phase IgM response, ne-
cessitating testing paired serum samples and prolonging
the time until diagnosis can be confirmed.
There is no universal consensus regarding what con-
stitutes the best respiratory specimen to be tested by
PCR. Combining nasopharyngeal and oropharyngeal
specimens may provide the greatest diagnostic yield.36
One study reported that sputum was superior to oropha-
ryngeal or nasopharyngeal specimens in young adults
with serologically proved M. pneumoniae infection.37
However, young children and many adults with mild ill-
ness often do not produce sputum, so nasopharyngeal or
oropharyngeal samples may be the only specimen types
available. In our experience, many children with severepneumonia requiring hospitalization will have positive
PCR results for M. pneumoniae on bronchoalveolar la-
vage fluid obtained by bronchoscopy.34
There have been few side-by-side comparisons to de-
termine whether one assay format or gene target is better
than another. Many of the comparisons that have been
done compared PCR using culture or serological analysis
as a reference method, and predictably yielded dispa-
rate results in some cases. The Centers for Disease Con-
trol and Prevention compared three real-time PCR assays
to detect M. pneumoniae.31 They performed triplicate
PCR assays using the Applied Biosystems ABI 7500 sys-
tem using two different TaqMan primer-probe sets target-
ing the ATPase gene and a new assay targeting the
CARDS toxin gene on 54 respiratory samples from an
outbreak in a college setting. Eighteen cases had posi-
tive results with all three assays. When dilutions of M.
pneumoniae reference strains were tested, the CARDS
toxin PCR assay consistently detected 1 to 5 colony-
forming units (CFUs), whereas the other two assays tar-
geting the ATPase genes detected 5 to 50 CFUs. Two
multicenter comparisons of various NAATs for M. pneu-
moniae detection38,39 reported significant variations in
test performance among participating laboratories, mak-
ing a strong case for an organized proficiency test pro-
gram, which is available in some European countries.40
In the United States, where there are no commercially
sold Food and Drug Administration–approved PCR as-
says for any Mycoplasma or Ureaplasma species, refer-
ence laboratories that offer their own internally developed
NAAT should participate in alternative proficiency testing,
in which clinical specimens are exchanged in a blinded
manner, or use the M. pneumoniae proficiency testing
specimens that are available through the College of
American Pathologists.
Both conventional and real-time nucleic acid se-
quence-based amplification (NASBA) have been used to
detect M. pneumoniae RNA.41 NASBA can provide rapid
results with sensitivity as good as or better than PCR, with
a detection threshold as low as 5 to 50 CFUs.41,42 This
assay has been described in monoplex and multiplex
format and has been developed as a commercial kit
(NucliSENS; bioMérieux, Marcy l’Etoile, France) sold in
various European countries. Multiplex PCR and NASBA
assays have been developed in a variety of formats for
detection of M. pneumoniae, along with Chlamydophila
pneumoniae and Legionella pneumophila.43–46 Generally
speaking, some loss in analytical sensitivity occurs in
multiplex assays when compared with monoplex assays
that may be related to incompatible amplification condi-
tions for multiple targets and the high concentration of
primers that can cause elevated background readings
and reduced efficiency. Although the multiplex NASBA
has potential to detect M. pneumoniae and C. pneumoniae
and Legionella species, it had a slightly lower sensitivity
than monoplex NASBA when applied to dilutions of wild-
type RNA generated in vitro.47 Other techniques, includ-
ing reverse line blot assays and microarrays, have been
used alone or in combination with multiplex PCR assays
for detection of M. pneumoniae and other respiratory
pathogens.33,45,46,48,49
; Uu, U
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been applied to detection ofM. pneumoniae in clinical spec-
imens using P1 sequences for primers in direct comparison
to real-time PCR.50 The assay was specific, with a detection
limit of 200 copies, and had 100% concordance with PCR
when applied to 95 nasopharyngeal specimens. The devel-
opment of commercial assays using this type of technology
for M. pneumoniae is anticipated because instrumentation
and reagents are undergoing clinical trials.
Commercial PCR assays have been available in Europe
for several years, and additional products are still in devel-
opment. Limited evaluations have shown they work in a
comparable manner to noncommercial assays.45,46,51
These assays include the Artus RepMp1 (Qiagen, Valencia,
CA), Venor Mp-QP (Minerva Biolabs, Berlin, Germany),
Chamylege (Argene Inc., Shirley, NY), and Pneumoplex
(Prodesse Inc., Waukesha, WI).
A comprehensive review of diagnostic methods for M.
pneumoniae respiratory tract infection, published by
Loens et al,28 indicated that, as of 2010, there were at
least 61 published in-house PCR assays for M. pneu-
moniae, many of which have been validated only for their
analytical sensitivity and not tested against many clinical
samples, or against one another. Some of the more re-
cently described real-time PCR assays for detection ofM.
pneumoniae and other species are listed in Table 2.
Macrolide resistance inM. pneumoniae is a major prob-
lem in Asia and is spreading to Europe and North Amer-
ica.6 PCR assays have been developed to detect three
major mutations in domain V of 23S rRNA that confer
high-level macrolide resistance in isolates of M. pneu-
moniae or directly in clinical specimens.34,60,61 A rapid
and inexpensive method that combines nested PCR, sin-
gle-stranded conformation polymorphisms, and capillary
electrophoresis can also detect macrolide-resistant mu-
tants directly from throat swabs.62 Finally, pyrosequenc-
ing has also been applied for detection of macrolide
resistance in M. pneumoniae and for strain typing.63
The UAB Diagnostic Mycoplasma Laboratory performs
Table 2. Examples of Real-Time PCR Assays for Detecting Myco
Specificity Target gene/region
Up and Uu 16S rRNA
Up Urease gene subunits and adjacent region
Up UU063
Up Urease gene subunits and adjacent region
Uu Urease gene subunits and adjacent region
Uu Urease gene subunits and adjacent region
Uu UUR10_0680
Mp P1
Mp repMp1 in P1
Mp CARDS toxin (mpn372)
Mp ATPase operon
Mp 16S rRNA
Mp 16S rRNA
Mg gap
Mg 16S rRNA
Mh gap
Mh yidC
Mg, M. genitalium; Mh, M. hominis; Mp, M. pneumoniae; Up, U. parvuma multiplex real-time PCR assay to detect point mutationsin all three positions of the 23S rRNA gene (2063, 2064,
and 2617) that are related to the macrolide resistance on
all clinical samples that are positive for M. pneumoniae in
the repMp1 real-time PCR assay. This assay uses fluo-
rescence resonant energy transfer hybridization probes
and the Roche LightCycler 2.0 instrument. This method is
based on the fact that nucleic acid will melt at a precise
temperature that is related to the nucleotide base com-
position. The presence of one or more point mutations in
23S rRNA that impair drug attachment to the bacterial
ribosome will be detected by this extremely sensitive
method, which can be completed in just a few hours. The
detection limit is as low as seven mutant molecules per
microliter in the PCR mixture.34 Figure 1 illustrates how
this assay detects and distinguishes the mutants.
Given the relatively mild clinical course of most myco-
plasmal respiratory tract infections, lack of widespread
availability of rapid diagnostic tests, and their associated
costs, many clinicians choose to treat empirically when
infection with this organism is strongly suspected. Test-
ing for M. pneumoniae would almost certainly become
more widespread in the United States if rapid real-time
PCR assays become more readily available so that test
results can play a greater role in guiding initial patient
management. Even if specimens have to be sent to a
reference laboratory with a longer turnaround time, it is
reasonable to pursue a comprehensive microbiological
diagnosis for patients with lower respiratory tract infec-
tions, including testing for M. pneumoniae by PCR, when
respiratory illness is of sufficient severity to warrant hos-
pitalization and no other causative microorganism is
readily apparent. Testing for M. pneumoniae should also
be considered if there is an unsatisfactory clinical re-
sponse to empirical treatment with macrolides because
this may indicate the presence of a macrolide-resistant
strain, in patients with an underlying comorbid condition
or immunodeficiency that would make severe and dis-
seminated disease more likely, and when there are sig-
and Ureaplasma Species in Clinical Samples
Analytical sensitivity
(genome copies or CFU/reaction) Ref. no.
10 copies Yoshida et al52
5 copies Mallard et al53
0.6 CFU Xiao et al22
10 copies Cao et al54
10 copies Cao et al54
5 copies Mallard et al53
0.8 CFU Xiao et al22
10 copies Pitcher et al55
0.2 CFU Dumke et al32
1–5 CFU Winchell et al31
5–50 CFU Winchell et al31
1 copy Khanna et al45
5 CFU Raggam et al44
5 copies Svenstrup et al56
10 copies Yoshida et al57
10 copies Baczynska et al58
7 copies Ferandon et al59
. urealyticum.plasma
s
s
s
snificant extrapulmonary symptoms present.
444 Waites et al
JMD September 2012, Vol. 14, No. 5M. genitalium
Although M. pneumoniae and M. genitalium are structur-
ally and antigenically related, they are genomically differ-
ent. Most of the early PCR assays targeted various re-
gions of the MgPa operon, but some have used the 16S
rRNA gene.64,65 Additional molecular-based assays, in-
cluding transcription-mediated amplification, have also
been used for epidemiological purposes.66–68 Quantita-
tive, rapid, real-time PCR assays have used targets such
as MgPa operon, 16S rRNA, the 115-kDa gene, and gap
encoding glyceraldehyde-3-phosphate dehydroge-
nase.56,57,68–72 It has become apparent that not all prim-
ers used in various studies react with all M. genitalium
strains, especially those using the MgPa target. Ma et
al73 examined the three genes of the M. genitalium MgPa
operon (mgpA, mgpB, and mgpC) and nine repetitive
sequences (termed MgPars) dispersed throughout the
genome in 15 geographically diverse strains. They dis-
covered that all operon sequences and all MgPars dif-
fered from each other more than from the published G37
operon sequence at both the nucleotide and deduced
amino acid levels. They determined that one of 19 prim-
ers contained up to 19 variable nucleotides and that the
target for one of two typing systems was located in a
hypervariable region, indicating the likelihood of errone-
ous results with some assays. This has been demon-
strated in studies using primers MGS-2 and MgPa-903.73
These data suggest that there is an efficient recombina-
tion system enabling generation of numerous variants
that may facilitate evasion of host defenses and that
additional research and development must be under-
taken to identify and validate the most appropriate PCR
primers for diagnostic testing.
In view of concerns for use of MgPa, and 98% identity
of the 16S rRNA gene for M. pneumoniae and M. genita-
lium, the UAB Diagnostic Mycoplasma Laboratory hasadapted the real-time PCR assay described by Sven-
strup et al56 for detection ofM. genitalium in clinical spec-
imens. This protocol targets the conserved housekeeping
gene gap (National Center for Biotechnology Information
accession number U39710) in a primer and probe sys-
tem. This target is different from other species, including
the gap homologue in M. pneumoniae (72.3% identity)
and is present in the genome as a single copy.56 PCR-
based assays have also been developed to detect mu-
tations in DNA gyrase and/or topoisomerase IV, mediat-
ing fluoroquinolone resistance in M. genitalium, thereby
circumventing the need for culture in vitro to determine
antimicrobial susceptibilities to these agents.74
Gen-Probe (San Diego, CA) has developed a tran-
scription-mediated amplification real-time PCR assay that
performs well compared with other methods, but it is
available in the United States only for research pur-
poses.68,75,76 Multiplex PCR-based systems for detection
of M. genitalium, along with Chlamydia trachomatis, Neis-
seria gonorrhoeae, and other urogenital mycoplasmas
and ureaplasmas, are sold as kits in several European
countries by multiple companies, including Bio-Rad (Her-
cules, CA), Amplex Biosystems (Giessen, Germany),
PCR Diagnostics.eu (Bratislava, Slovak Republic), and
Seegene, Inc. (Rockville, MD), using various formats and
instrument platforms.
Because the requirements for marketing diagnostic
products in Europe are not as stringent as those in the
United States, mandated by the Food and Drug Admin-
istration, many products sold there have not been sub-
jected to large and rigorous clinical trials or comparisons
with existing assays.
Lack of commercial NAATs for detection of M. genita-
lium in the United States has greatly limited interest
among physicians in seeking this mycoplasma in clinical
Figure 1. Real-time PCR detection of macrolide-
resistant M. pneumoniae in clinical samples.
Genomic DNA samples of two patients contain-
ing the A2063G mutation, verified by sequenc-
ing, are purified and tested together with a wild-
type (WT) control (M. pneumoniae strain M129,
ATCC number 29342). Melting curves (A and B)
and corresponding melting peaks (C and D) are
shown. A2063/A2064 mutations are analyzed in
channel 610 (A and C). The WT melting peak is
67.31°C, whereas the melting temperature (Tm)
of A2063G mutants is 63.25°C  0.04°C. Thus, a
4°C difference between WT and mutant is ob-
served. The C2617 assay is shown in channel 705
(B and D). Because all samples do not have
mutations at this position, they show similar WT
Tm values of approximately 68°C, as predicted.
Data are reproduced from Xiao et al,34 with per-
mission of Walters Kluwer Health (copyright
2009).specimens. Given the importance of this mycoplasma in
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matory disease, and the likelihood of venereal transmis-
sion of disease to other individuals, use of accurate mo-
lecular-based assays with a rapid turnaround time would
undoubtedly increase if they become available. If M.
genitalium is detected in the lower urogenital tract of a
symptomatic patient, it should be considered medically
significant.
M. hominis
Conventional PCR assays for M. hominis have mainly
used 16S rRNA as a gene target.77,78 Because some
heterogeneity has been reported in the 16S rRNA gene of
M. hominis,79 other targets, including gap, fstY, and yidC,
have been developed.58,59,80 The UAB Diagnostic Myco-
plasma Laboratory uses a real-time PCR assay to detect
M. hominis in clinical specimens targeting gap (National
Center for Biotechnology Information accession number
AJ243692) using the Roche LightCycler 2.0, as adapted
from Baczynska et al.58
Because M. hominis is a common commensal in the
female cervix and vagina and the male urethra, a positive
PCR result on specimens from such sites may not be
meaningful in the absence of clinical manifestations
known to be associated with this organism. However, if
the M. hominis load reaches 104 CFU/mL, this can be a
crucial criterion for urogenital infections in women.81 In
the case of extragenital specimens in adults or neonates,
a positive M. hominis PCR assay or culture result should
be considered clinically significant. There are many re-
ports of systemic infections that were caused byM. homi-
nis and for which diagnosis was delayed simply as a
result of delays in appropriate testing because no one
attempted to test.
Ureaplasma Species
PCR assays are important to detect and identify the indi-
vidual Ureaplasma species for research purposes. Gel-
based conventional PCR assays targeted sequences of
16S rRNA and 16S rRNA to 23S rRNA intergenic spacer
regions, the urease gene, and mba,82–90 whereas real-
time PCR assays have mainly targeted the urease genes
and their subunits or mba.22,53,54,57,91,92 Yoshida et al78
described a conventional PCR assay applied to urine
specimens of patients with urethritis targeting 16S rRNA
genes of M. genitalium, M. hominis, U. parvum, and U.
urealyticum. After amplification, PCR products were then
subjected to hybridization assays using four species-
specific capture probes to detect the targets. When com-
pared with direct sequencing, this technique produced
similar results and no cross-reactivity.
The UAB Diagnostic Mycoplasma Laboratory performs
a real-time PCR assay for detection and differentiation of
Ureaplasma species based on UU063 (NP_077893),
which encodes a conserved hypothetical protein that is
identical in all four U. parvum serovars and a 15,072-bp
open reading frame, UUR10_0680 (NC_011374.1), that is
conserved (99.97%) in all 10 U. urealyticum serovars.22This assay detected more positive clinical specimensthan a conventional PCR assay based on a urease gene
target in intralaboratory method evaluations.
Some molecular-based assays that include detection
of Ureaplasma species are commercially available in var-
ious European countries, but not in the United States.
Seegene, Inc. markets their products STD6 and STD6B
ACE Detection, which simultaneously detect Trichomonas
vaginalis,M. hominis,M. genitalium,C. trachomatis,N. gon-
orrhoeae, and Ureaplasma species in endocervical/ure-
thral swabs. The novel feature of the Seegene, Inc., tech-
nology is a dual-priming oligonucleotide system that
contains two separate priming regions linked by a
polydeoxyinosine spacer.93 The Seegene, Inc., STD6
ACE kit works with any thermocycler, and the post-PCR
assay is designed for either manual or automated gel
electrophoresis. The STD6 Ureaplasma assay amplifies a
130-bp region of the ureD cassette.94 Their new version,
STD6B, differentiates U. urealyticum from U. parvum ureC
genes. Other companies, including PCR Diagnostics.eu
and Amplex Biosystems, have PCR-based diagnostic
products to detect Ureaplasma species in clinical speci-
mens. PCR Diagnostics.eu has an assay in traditional
PCR format with detection of PCR products on agarose
gels that will differentiate the two Ureaplasma species.
The multiplex PCR/reverse line blotting assay method has
been used to detect numerous respiratory pathogens,
including M. pneumoniae and urogenital pathogens, in-
cluding both Ureaplasma species, M. genitalium, and M.
hominis.95–97 Examples of real-time PCR assays used for
detection and differentiation of Ureaplasma species are
shown in Table 2.
Such asM. hominis, Ureaplasma species are also com-
mon commensals in the lower urogenital tracts of healthy
people. Therefore, a positive PCR assay or culture result
from specimens from these sites is usually expected. It is
the increased bacterial load determined by real-time PCR
or quantitative culture that can sometimes be valuable as
a clinical indication of infection.52 Positive PCR or culture
results for Ureaplasma species from the urethra in men
with urethritis, from tracheal aspirates of neonates with
respiratory distress, from the bloodstream or cerebro-
spinal fluid in neonates with pleocytosis, and from nor-
mally sterile extragenital sites should be considered
diagnostic of clinically significant infection. Ureaplasma
species can be relatively common opportunistic patho-
gens causing systemic infections involving various
body sites in immunosuppressed people; many of
them are missed initially because they are not consid-
ered, and diagnostic tests are performed only after
treatment with antimicrobials that are not active against
these organisms has failed.
Xiao et al98 evaluated 1061 clinical isolates of Urea-
plasma species from various patient populations and
found that U. urealyticum, but not U. parvum, was associ-
ated with male urethritis, as noted by others.20,52 Even
though there have been conflicting reports regarding dif-
ferential pathogenicity of the two Ureaplasma species,
there is no compelling necessity to identify ureaplasmas
to the species level in most circumstances because an-
timicrobial treatment would not differ. The only possible
exception would be cases of male urethritis, in which
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that U. parvum, if detected alone by PCR, might not war-
rant treatment. However, because the real-time PCR as-
say we use for diagnostic purposes uses gene targets
that enable species distinction, the specific organisms
that are detected are reported whenever there is a pos-
itive result. As mentioned earlier, our laboratory still pro-
vides culture as the primary means for Ureaplasma de-
tection for clinical purposes, and we perform PCR only by
special request or for research studies.
Important Technical Aspects of Molecular-
Based Assays Used for Mollicute Detection
Specimen Collection
All clinical specimens suitable for culture are acceptable
for diagnostic testing for mycoplasmas and ureaplasmas
by molecular methods if they are collected, stored, and
processed correctly. Blood should be collected in a tube
containing acid citrate dextrose. Other specimens can be
inoculated into transport media, culture media, or PBS at
collection or as soon as possible thereafter. For swab
specimens, use of only Dacron or polyester swabs as
calcium alginate and cotton swabs can be inhibitory. The
10 B or SP 4 broths used for culture do not have any
deleterious effect on performance of the real-time PCR
assay using the Roche LightCycler 2.0 (Roche Applied
Science, Penzberg, Germany), but it is possible that cul-
ture broth could be inhibitory when using other primers or
reaction conditions, or thermocyclers. Thus, it is manda-
tory to verify that culture broth or any liquid other than a
designated PCR transport buffer is not inhibitory before
using it for PCR transport.
DNA Extraction
Lysis and proteinase K treatment usually yield PCR-de-
tectable DNA, unless the specimen is inhibitory.99 Suit-
able specimens for this procedure include body fluids
(other than blood) and transport systems containing ma-
terial obtained from swabs. Potentially inhibitory speci-
mens, including blood, tissue samples, lower respiratory
tract secretions, and subcultures, may be purified by the
QIAamp DNA Blood Mini Kit (Qiagen) or other commer-
cial genomic DNA purification kits. Automated or semi-
automated nucleic acid isolation methods, such as Qia-
gen BioRobot EZ1 (Qiagen), NucliSENS (bioMérieux),
easyMAG (bioMérieux), or MagNaPure LC (Roche Ap-
plied Science), can also be used to prepare samples.
Some automated extraction systems appear to work as
well as manual systems. The easyMAG nucleic acid ex-
tractor actually enabled superior amplification results for
M. pneumoniae when applied retrospectively to clinical
specimens when compared with the QIAgen blood mini
kit and the NucliSENS miniMAG systems.100,101PCR Programs and Operating Conditions
Most aspects of the real-time PCR procedures are instru-
ment and protocol specific, such that analytic sensitivity,
specificity, primer selection, and all aspects of the oper-
ating program must be validated separately for each
method and instrument. Each laboratory must perform an
evaluation of every assay component, from sample type,
transport media, and extraction method, to final PCR
amplification and detection procedures using the spe-
cific primers and probes, reaction conditions, and con-
trols applicable to the assay to ensure that the techniques
are valid and that there is no PCR inhibition at any step.
Quality Control
Careful attention to quality control procedures should
limit the risk of false-positive and false-negative results.
False-positive results from contamination can be a major
problem for conventional PCR, but are less problematic
with real-time PCR. In addition to human errors, reasons
for false-negative results include the presence of PCR
inhibitors in the specimen, suboptimal reagent prepara-
tion and reaction conditions, and inefficient extraction of
the target DNA. Inhibitory factors and suboptimal PCR
conditions can be detected by adding a positive control
DNA after purification. However, this external control
strategy cannot reveal inefficient DNA extraction. Use of
an internal control added directly to the crude sample
and coprocessed for purification and amplification is the
most accurate method to monitor the important steps of
diagnostic PCR protocols.
Determination of Analytical Sensitivity and
Specificity
The PCR analytical sensitivity test should be performed
against serial dilutions of template DNA, either bacterial
genomic DNA from a defined inoculum titer or a plasmid
containing the target sequence, and can be expressed in
terms of amount of DNA detected or numbers of organ-
isms (CFUs). Published or commercially sold PCR assays
used for diagnostic purposes can reasonably be ex-
pected to detect 102 CFUs of the targeted organism.
The analytical specificity of PCR assays should be
tested against all other human mollicutes, including com-
mensal mycoplasmal species and other bacteria that
may appear in the same body locations or show se-
quence similarities to the targets. An assay should be
validated against various type strains and low-passage
clinical isolates. For M. pneumoniae, strains representing
both of the main P1 subtypes should be included. For U.
parvum, the four recognized serovars should be includ-
ed; and for U. urealyticum, the 10 known serovars should
be tested. Human genomic DNA should always be in-
cluded in the evaluation because of its presence in clin-
ical specimens and possible inhibitory effects. The assay
reproducibility should be verified by testing the same
samples multiple times.
Molecular Detection of Mycoplasmas 447
JMD September 2012, Vol. 14, No. 5Additional PCR Assay Validation
It is important to perform PCR assays on well-character-
ized clinical specimens, with or without the organism of
interest, that have been tested by other acceptable meth-
ods, such as culture and other PCR assays using differ-
ent gene targets. Before a laboratory can begin routine
PCR-based diagnostic work, it must be able to demon-
strate that its molecular results compare favorably or
exceed the detection ability of conventional culture-
based techniques to establish a clinical sensitivity for the
assay. The lack of comprehensive published compara-
tive data for validation of the wide variety of PCR assays
used for detection of human mycoplasmas and ureaplas-
mas remains a significant shortcoming.
Summary and Conclusions
Development and application of molecular-based meth-
ods during the past two decades has significantly im-
proved the ability to detect and identify mycoplasmas
and ureaplasmas in clinical specimens, enabled expan-
sion of knowledge about the diseases they may cause,
and provided more rapid and accurate diagnosis. It has
also heightened interest in obtaining diagnostic testing
for these organisms among many clinicians. This has
been especially true forM. pneumoniae andM. genitalium,
for which real-time PCR methods are clearly the diagnos-
tic methods of choice. NAAT-based detection methods
have lessened the reliance on the problematic serologi-
cal detection systems. The enthusiasm for development
of NAAT-based systems for application in mycoplasmol-
ogy has resulted in dozens of published assays using a
broad array of gene targets and methods. When used for
diagnostic or epidemiological purposes in a clinical set-
ting, there is justifiable concern over accuracy because
most assays have never been sufficiently validated
against other molecular- or culture-based methods to
ensure their accuracy. Because none of these assays
has thus far been evaluated or approved by the Food and
Drug Administration, much is still unknown about their
sensitivity and specificity. The few comparative clinical
studies of various NAATs and preliminary studies of in-
terlaboratory proficiency testing have indicated that there
are considerable differences with these assays for detec-
tion of mycoplasmal infections, as well as the capabilities
of the individual testing laboratories. The future of diag-
nostic mycoplasmology and epidemiological research
rests with molecular-based technology, although culture,
phenotypic methods, and traditional antimicrobial sus-
ceptibility testing will still have an important role, espe-
cially for M. hominis and Ureaplasma species. Therefore,
it is important that large-scale comparisons must be per-
formed to compare reproducibility and accuracy of
NAATs. This must include side-by-side comparisons of
new assay formats and gene targets with existing assays
using the same, and different, targets and with other
established methods, including culture. Such compari-
sons should ideally include a broad selection of speci-
men sources from different geographic areas. Eventually,it seems likely that commercial development of NAATs for
all of the important pathogenic mycoplasmal and ure-
aplasmal species that infect humans will come to the
United States, as they have to Europe. Standardization of
reagents and rigorous quality control would then be more
realistic.
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